Hematology Clinical Trials

Statistical methods in hematology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All hematology trials

585 results

• Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00267059).Phase 2Results postedn = 45NCT00267059
• Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 30NCT01316523
• Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 49NCT01351896
• Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 8NCT02589145
• Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 33NCT00439231
• Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 77NCT00966693
• Lighting Intervention for Cancer-related Fatigue: Complete Statistical AnalysisIndependent statistical analysis of Lighting Intervention for Cancer-related Fatigue: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04827446).Phase NAResults postedn = 139NCT04827446
• Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 48NCT01804101
• Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients: Complete Statistical AnalysisIndependent statistical analysis of Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 7NCT02481297
• Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006): Complete Statistical AnalysisIndependent statistical analysis of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03483103).Phase 2Results postedn = 74NCT03483103
• Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study: Complete Statistical AnalysisIndependent statistical analysis of Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 187NCT03733249
• Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) – Extension Study: Complete Statistical AnalysisIndependent statistical analysis of Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 1Results postedn = 1NCT02002936
• LOTIS-9Independent statistical analysis of A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 41NCT05144009
• Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease: Complete Statistical AnalysisIndependent statistical analysis of Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 164NCT00929695
• LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 17NCT00610883
• M14-032Independent statistical analysis of M14-032, a phase 2 single-group study of venetoclax in chronic lymphocytic leukemia after relapse or refractory disease following B-cell receptor signaling pathway inhibitor therapy.Phase 2Results postedn = 127NCT02141282
• MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 13NCT01380145
• Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE): Complete Statistical AnalysisIndependent statistical analysis of Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01525875).Phase 2Results postedn = 44NCT01525875
• MAGNIFYIndependent statistical analysis of Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 503NCT01996865
• MAJICAn independent statistical analysis of the phase 3 MAJIC trial evaluating acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.Phase 3n = 607NCT05057494
• Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia: Complete Statistical AnalysisIndependent statistical analysis of Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 4NCT03195010
• Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 299NCT04459416
• Massive Iron Deposit Assessment: Complete Statistical AnalysisIndependent statistical analysis of Massive Iron Deposit Assessment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01572922).Phase NAResults postedn = 142NCT01572922
• MATOCSSIndependent statistical analysis of Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1/2Results postedn = 10NCT00527566
• Mature B-Cell Lymphoma And Leukemia Study III: Complete Statistical AnalysisIndependent statistical analysis of Mature B-Cell Lymphoma And Leukemia Study III: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01046825).Phase 2/3Results postedn = 128NCT01046825
• MEDALISTIndependent statistical analysis of A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 229NCT02631070
• Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 40NCT00743288
• MERCURIndependent statistical analysis of A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 184NCT00559637
• Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 1NCT00726830
• Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 59NCT00003910
• Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage: Complete Statistical AnalysisIndependent statistical analysis of Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 37NCT00905034
• Microvascular Blood Flow in Sickle Cell Anemia: Complete Statistical AnalysisIndependent statistical analysis of Microvascular Blood Flow in Sickle Cell Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01566890).Phase NAResults postedn = 91NCT01566890
• MiniCliniIndependent statistical analysis of Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 2NCT02277639
• MMVAR – Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation: Complete Statistical AnalysisIndependent statistical analysis of MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 269NCT00256776
• Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 7NCT02429375
• Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 41NCT04626791
• MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 24NCT00462605
• MUCINIndependent statistical analysis of Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 140NCT01769248
• Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 49NCT00965250
• Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA: Complete Statistical AnalysisIndependent statistical analysis of Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 79NCT03523117
• Music Therapy in Sickle Cell Pain Mixed Methods Study: Complete Statistical AnalysisIndependent statistical analysis of Music Therapy in Sickle Cell Pain Mixed Methods Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02270060).Phase NAResults postedn = 60NCT02270060
• Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft: Complete Statistical AnalysisIndependent statistical analysis of Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1/2Results postedn = 15NCT00814983
• Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL: Complete Statistical AnalysisIndependent statistical analysis of Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1Results postedn = 22NCT05507827
• Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 35NCT02120157
• myOpportunITy2Independent statistical analysis of A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP): primary endpoint results, effect estimate…Phase 3Results postedn = 30NCT04224688
• myOpportunITy3Independent statistical analysis of A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP): primary endpoint results, effect estimate…Phase 3Results postedn = 43NCT04596995
• N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC): Complete Statistical AnalysisIndependent statistical analysis of N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03759639).Phase 2Results postedn = 33NCT03759639
• NATRONIndependent statistical analysis of A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 134NCT04191304
• NB-001 in Children and Adolescents With 22q11 Deletion Syndrome: Complete Statistical AnalysisIndependent statistical analysis of NB-001 in Children and Adolescents With 22q11 Deletion Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05290493).Phase 2Results postedn = 37NCT05290493
• NEON-1Independent statistical analysis of NEON-1, a phase 1 study of ALPN-202 in subjects with advanced malignancies, including trial design, endpoints, statistical methodology, and interpretation.Phase 1n = 62NCT04186637

← All therapeutic areas